regadenoson · Astellas · NDA 022161
Lexiscan
Earliest generic entry, as listed
2 Feb 2027
Blocked by patent: US 8106183, US RE47301.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8106183 | drug substance · sets the listed date | 2 Feb 2027 |
| US RE47301 | drug product · sets the listed date | 2 Feb 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Enters 12-month window basis: patent · 022161-001Listed date 2 Feb 2027Detected 24 Oct 2026
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022161 · 001 · RLD | solution, intravenous | 0.4MG/5ML (0.08MG/ML) | 2 Feb 2027 |